CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 120 enrolled
Drug / intervention
temozolomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00313729
NCT00313729Phase 2Completed
CompareCT.gov

A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients With Supratentorial Low Grade Glioma

University of California, San Francisco·interventional·Posted Apr 12, 2006·Updated Feb 7, 2019

In Brief

A Phase 2 clinical trial evaluating temozolomide for CNS Tumor, Adult. Completed, enrolled 120 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with supratentorial low-grade glioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCNS Tumor, Adult
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 12, 2006
Enrollment StartMay 1, 1999
Primary CompletionSep 25, 2014
Study CompletionJun 12, 2017
TodayJul 2, 2026
Enrollment to primary: 15.4 yearsPosted 20.2 years ago

Interventions

temozolomidedrug

Chemotherapy